// App-Quantinova.ai

3115 : Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).

Researchers

Presenter

  • Sarah E. R. Halford

Principal Investigators

  • Harriet Walter

  • Pamela McKay

  • William Townsend

  • Kim Linton

  • Kathrin Heinzmann

  • Ilaria Dragoni

  • Laura Brotherton

  • Gareth Veal

  • Alexandros Siskos

  • Hector C Keun

  • Chris Bacon

  • Steve Wedge

  • George Petrides

  • Martin J.S. Dyer

  • Elizabeth Ruth Plummer

Medical Centers

  • Cancer Research UK Centre for Drug Development, London, United Kingdom

  • The Ernest and Helen Scott Haematological Research Institute, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Cancer Research UK & UCL Cancer Trials Centre, London, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Cancer Research UK, Southampton, United Kingdom

  • Northern Institute for Cancer Research Newcastle University, Newcastle, United Kingdom

  • Kings College London, London, United Kingdom

  • Northern Institute for Cancer Research, Newcastle University, Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Burkitt lymphoma

  • B cell lymphomas

Biomarkers

  • 18F-fluorodeoxyglucose

  • Monocarboxylate transporter 4

Drug/Treatment

  • AZD-3965

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Expansion Study

  • Cohort

Phase

  • I

Study Id's

  • NCT01791595

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved